AACAP

First Randomized Controlled Trial Comparing Woebot to Clinician-Led Psychotherapy Reveals Digital Mental Health Intervention Is Non-Inferior in Reducing Depressive Symptoms Among Teens

Retrieved on: 
Thursday, October 26, 2023
Mental Health, Health, Consumer, Apps, Applications, Technology, Teens, Cognitive behavioral therapy, Adolescence, Triage, Mental, Clinical trial, MD, Journal of the American Academy of Child and Adolescent Psychiatry, Doctor of Philosophy, Research, CHKD, Multimedia, Pediatrics, Union, White, American Academy, AACAP, Eastern Virginia Medical School, African Americans, CBT, Safety, Depression, Anxiety, Bentham Science Publishers, Patient, Grammatical mood, Patient Health Questionnaire, Mental health, Nursing, Child

The results were presented in a poster presentation at the American Academy of Child and Adolescent Psychiatry ( AACAP ) conference.

Key Points: 
  • The results were presented in a poster presentation at the American Academy of Child and Adolescent Psychiatry ( AACAP ) conference.
  • View the full release here: https://www.businesswire.com/news/home/20231026083262/en/
    This is the first known study to compare an agent-based digital mental health intervention to a therapist-led therapeutic intervention in a real-world clinical setting.
  • The findings suggest a potential role for W-GenZD within outpatient mental health care clinics to address the ongoing adolescent mental health crisis.
  • A non-inferiority test was used to evaluate the study aim comparing the reduction in PHQ-8-measured depression symptoms between the two interventions at the end of treatment.

Newport Healthcare Takes the Stage at the American Academy of Child and Adolescent Psychiatry (AACAP) 70th Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023
LMFT, Adolescence, Education, Hope, DBT, Medicine, Family therapy, PCIT, Doctor of Philosophy, Research, National Directorate for Personal Data Protection, Newport, American Academy, Convention, Dialectical behavior therapy, Annual general meeting, ARC, Bentham Science Publishers, Patient, Mental health, Birth control, Nursing, MD, Child, AACAP

NASHVILLE, Tenn., Oct. 25, 2023 /PRNewswire/ -- This week marks the 70th Annual Meeting for the American Academy of Child and Adolescent Psychiatry (AACAP), and the nation's leading provider of evidence-based mental health treatment for youth, young adults, and families, Newport Healthcare , is set to take the stage twice in New York City.

Key Points: 
  • NASHVILLE, Tenn., Oct. 25, 2023 /PRNewswire/ -- This week marks the 70th Annual Meeting for the American Academy of Child and Adolescent Psychiatry (AACAP), and the nation's leading provider of evidence-based mental health treatment for youth, young adults, and families, Newport Healthcare , is set to take the stage twice in New York City.
  • Newport's first presentation is chaired by Medical Director Mirela Loftus, MD, PhD, and co-presented by National Director of Family Therapy Services Samantha Quigneaux, LMFT.
  • AACAP's Annual Meeting is the largest gathering of child and adolescent psychiatrists in the world with attendees representing over 56 countries.
  • For more information about Newport Healthcare including treatment locations , affordability/accessibility , and outcomes research , visit NewportHealthcare.com.

ZAGG Introduces XTR3 Screen Protection and Graphene-Infused Cases for iPhone 15 Range of Smartphones

Retrieved on: 
Tuesday, September 12, 2023
Life, Denali, Apple Watch, Aviation, Forest, SALT, Courage, MagSafe, IPhone, PNAS, IPad, AACAP, Apple Inc., American Academy of Child and Adolescent Psychiatry, Target, 2000s, Proceedings of the National Academy of Sciences of the United States of America, Diamond, Apple, Growth, Verizon Communications, T-Mobile, AT&T, Plastic, Melatonin, AT, Guard, Sleep, Zagg, Certification, Somnolence, Glass, Crystal Palace, FSC, FED, Sand, Screen time, Table tennis rubber, HEV, Bentham Science Publishers, Friction, National academy, Dust, Science, DEM, Blue, Mobile phone, Television, Telescopic sight, Consumer electronics, Audit, Child, Graphene, Kickstand, Walmart

SALT LAKE CITY, Sept. 12, 2023 (GLOBE NEWSWIRE) -- ZAGG ®, the global leader in accessories and technologies that empower mobile lifestyles, today announced XTR3 screen protection and protective cases infused with Graphene, one of the strongest materials on earth.1 The new screen protectors and cases are available for iPhone 15 , iPhone 15 Plus , iPhone 15 Pro , and iPhone 15 Pro Max .

Key Points: 
  • SALT LAKE CITY, Sept. 12, 2023 (GLOBE NEWSWIRE) -- ZAGG ®, the global leader in accessories and technologies that empower mobile lifestyles, today announced XTR3 screen protection and protective cases infused with Graphene, one of the strongest materials on earth.1 The new screen protectors and cases are available for iPhone 15 , iPhone 15 Plus , iPhone 15 Pro , and iPhone 15 Pro Max .
  • Glass XTR3 also includes an anti-dust adhesive that installs smoothly over most dust, so it disappears on your screen.
  • “ZAGG screen protectors and cases exist where strength meets innovation and redefine the meaning of mobile phone protection,” said Brad Bell, senior vice president of global marketing for ZAGG.
  • 1 selling brand for smartphone screen protection in the U.S. and has set the industry standard for screen protection.

Leading child mental health organisations call for global action against infant, child and adolescent trauma

Retrieved on: 
Thursday, June 1, 2023
Learning, SCAP, American Academy of Child and Adolescent Psychiatry, Society, Child and adolescent psychiatry, International Association for Child and Adolescent Psychiatry and Allied Professions, Disability, AACAP, Supervised visitation, Mental health, Institute of Psychiatry, Psychology and Neuroscience, International Association, American Academy, Adverse childhood experiences, King's College London, Academy of Medicine, DSM-IV codes, Bentham Science Publishers, National Children's Mental Health Awareness Week, ASCAP, Royal Australian and New Zealand College of Psychiatrists, ACeS, Journal of Indian Association for Child and Adolescent Mental Health, International Society, Growth, Trauma, IACAPAP, Infant, Adolescence, Nursing, Birth control, Toy, Psychology, Neuroscience, Psychotherapy, Child, Psychiatry, Research

To address this pressing concern and mobilise global efforts, the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), International Society for Adolescent Psychiatry and Psychology (ISAPP), World Association for Infant Mental Health (WAIMH), and World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD).

Key Points: 
  • To address this pressing concern and mobilise global efforts, the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), International Society for Adolescent Psychiatry and Psychology (ISAPP), World Association for Infant Mental Health (WAIMH), and World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD).
  • This year witnessed the second annual WICAMHD event under the theme of Stand Against Infant, Child and Adolescent Trauma.
  • Dr Dennis Ougrin, Consultant Child and Adolescent Psychiatrist, Visiting Professor of Child and Adolescent Psychiatry and Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London discussed the impacts of the war in Ukraine.
  • These include the Indian Association for Child and Adolescent Mental Health (IACAM), the Lithuanian Society of Child and Adolescent Psychiatry (LVPPD), the American Academy of Child and Adolescent Psychiatry (AACAP), the Austrian Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (ASCAP) and the Section of Child and Adolescent Psychiatry, College of Psychiatrists, Academy of Medicine, Singapore (SCAP).

New Psychiatric Clinic "Fermata" Focuses on Rapid Treatment of Depression and OCD in Just 5 Days

Retrieved on: 
Tuesday, March 21, 2023
Well, American Academy of Child and Adolescent Psychiatry, Telehealth, Frontier Psychiatrist, Brainsway, McMillan, Depression, Emergency medicine, OCD, TMS, AACAP, Stanford University, Medicine, American Academy, International Conference on Population and Development, Research, Private practice, Magnetic resonance, Continuing medical education, Bentham Science Publishers, Patient, Muir, Annual general meeting, ICEM, Conference, Clinical, SXSW, SAINT, Pharmaceutical industry, Medical device, Nursing, Fermata, Child

At Fermata, patients can receive accelerated deep transcranial magnetic stimulation (TMS), a non-invasive, safe, and medication-free treatment option that has shown remarkable results in the real world patients for depression and OCD .

Key Points: 
  • At Fermata, patients can receive accelerated deep transcranial magnetic stimulation (TMS), a non-invasive, safe, and medication-free treatment option that has shown remarkable results in the real world patients for depression and OCD .
  • He continues: "Whereas the Stanford team used fMRI to guide their treatment, Fermata uses more modern H-coil deep TMS systems by Brainsway to achieve similar results."
  • As a technology-driven clinic, Fermata is committed to providing patients with the best possible care using cutting-edge technology.
  • "We are excited to bring a treatment that works in under a week for depression and OCD to our clients," said Dr. Owen Muir, co-founder of Fermata.

NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry

Retrieved on: 
Monday, October 17, 2022
Monarch, Caregiver, American Academy of Child and Adolescent Psychiatry, Diagnosis, Anticonvulsant, Attention deficit hyperactivity disorder, ADHD, Patient, Depression, AACAP, United, OMICS Publishing Group, American Academy, GLOBE, Telephony, FDA, Pharmaceutical industry, Medicine, Child

LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , aLos Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.

Key Points: 
  • LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , aLos Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.
  • The Monarch eTNS System is a bioelectronic medical device that uses external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric disorders.
  • In 2019, the Monarch eTNS System became the first-ever medical device cleared by FDA for treating pediatric ADHD.
  • The company is commercializing the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA.

Vida Health Boosts its Clinical Team With Two New Additions

Retrieved on: 
Tuesday, February 8, 2022
Mental Health, Health, Diabetes, Fitness & Nutrition, Managed Care, General Health, University of Michigan School of Social Work, Depression, Hypertension, Mount Sinai Hospital, School, Emory, Visa, Multimedia, Medicare, Public health, Faculty, Research, Anxiety, SVP, Cisco Systems, Medicaid, Adolescence, Risk, Patient, Icahn School of Medicine at Mount Sinai, Blue Cross Blue Shield Association, University, Adult, Substance Abuse and Mental Health Services Administration, Medical director, CHOP, American Academy, Â, EBay, American Academy of Child and Adolescent Psychiatry, Medical Affairs Bureau, Health care, AACAP, Diabetes, Weight loss, DRS, University of Texas Southwestern Medical Center, VP, Medicine, Child, Psychiatry, Boeing, Medicine, Health, Humana

The additions boost Vidas clinical team as it doubles down on providing value-based care to its members and clients.

Key Points: 
  • The additions boost Vidas clinical team as it doubles down on providing value-based care to its members and clients.
  • Krysti Lan Chi Vo and Richard Frank have joined Vida Health as VP, Head of Psychiatry, and SVP of Medical Affairs, respectively.
  • Vida has proven clinical outcomes across a range of conditions, including diabetes, depression, hypertension, anxiety, and weight loss.
  • Vida Health is a virtual care company intentionally designed to treat mental and physical conditions together.

Array Behavioral Care CEO to Speak on Capitol Hill and Advocate for Pediatric Mental Health and TREATS Act

Retrieved on: 
Wednesday, December 1, 2021
Biotechnology, General Health, Mental Health, Other Health, Health, Patient, Research, Pediatrics (journal), Mental health, Psychiatry, Senate, School, Technology, United States Public Health Service, AACAP, Hospital, Array, Self-harm, American Academy of Child and Adolescent Psychiatry, Boyce, IV, Prescription, Education, Solution, MAT, COVID-19, Legislation, Telehealth, Adolescence, Center, Substance-related disorder, Adult, Capitol Hill, OnDemand, The Greatest AtHome Videos, American Hospital Association, Computer network, III, American Telemedicine Association, Congress, Association, 1964 NFL Draft, American Academy, Pharmaceutical industry, Medicine

Boyce is a recognized leader and advocate on mental health issues of critical importance including how care is accessed, measured, designed, and delivered.

Key Points: 
  • Boyce is a recognized leader and advocate on mental health issues of critical importance including how care is accessed, measured, designed, and delivered.
  • Boyces appearance on Capitol Hill and subsequent participation in an upcoming mental health conference are organized through the Center for Telehealth & e-Health Law (CTeL).
  • The TREATS Act, introduced in February 2021, proposes to permit the prescribing of certain controlled substances via telemedicine for mental health services.
  • Despite the heightened need for mental health care, the number of psychiatrists and therapists to care for the mental health needs of children has not kept pace.

NextGen Healthcare Partners with Prominent Psychiatrist Dr. Gail Saltz to Shine Light on Mental Health Support

Retrieved on: 
Thursday, November 18, 2021
Software, Practice Management, Networks, General Health, Health, Mental Health, Technology, Security, Patient, News, Pediatrics (journal), Anxiety, Mental health, Psychiatry, Technology, AACAP, Teaching hospital, NextGen Healthcare, American Academy of Child and Adolescent Psychiatry, AAP, COVID-19, EST, Nasdaq, Twitter, National Alliance on Mental Illness, American Hospital Association, National Alliance, Instagram, Hospital, EHR, NAMI, CHA, Nextgen, Weill Cornell Medicine, LinkedIn, Mental disorder, Clinical Associate (Psychology), American Academy, PM, Adolescence, YouTube, Medicine, Software, Practice Management, Networks, General Health, Health, Mental Health, Technology, Security, Dr. Gail Saltz, NextGen Healthcare, Inc., DR. GAIL SALTZ, NEXTGEN HEALTHCARE, INC.

According to the National Alliance on Mental Illness ( NAMI ), one in five Americans lives with a mental health condition.

Key Points: 
  • According to the National Alliance on Mental Illness ( NAMI ), one in five Americans lives with a mental health condition.
  • I am proud to partner with NextGen Healthcare again to highlight information about the connection between mental and physical health as an integral part of whole-person care.
  • We know that mental health is suffering for so many right now, and it needs to be addressed systemically within the healthcare industry, said Dr. Saltz.
  • Tune in to the event at 1 p.m. EST on Nextgens Facebook or LinkedIn page for a discussion about mental health resources and the relationship between mental and physical health.

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Safety, University, ADHD, American Academy of Child and Adolescent Psychiatry, Central nervous system disease, Coronavirus Scientific Advisory Board (Turkey), Narcolepsy, Sexual abuse, PD, MD, Attention deficit hyperactivity disorder, Clinical trial, U.S. Securities and Exchange Commission, Report, NASDAQ, Doctor of Philosophy, Plasma protein binding, Growth, Methylphenidate, SEAL, Forward-looking statement, Program, SAB, CNS, Twitter, American Academy, AACAP, Automated ECG interpretation, Company, Annual general meeting, Catalent, Research, LinkedIn, Solution, GLOBE, Vital signs, Amphetamine, Stephen Faraone, 4-way, Central nervous system, Patient, FDA, IND, Pharmaceutical industry

PHILADELPHIA, PA, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2021.

Key Points: 
  • We are pleased with the progress made over the course of the third quarter.
  • Patient enrollment remains ongoing with the final patient visit and completion of treatment expected in the first quarter of 2022 with topline results expected shortly thereafter.
  • Research and development expenses were $0.2 million and $0.7 million for the three months ended September 30, 2021 and 2020, respectively.
  • General and administrative expenses were $1.0 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively.